Antibodies
Researchers have made a significant discovery in the treatment of psoriasis, a chronic autoimmune disease that affects millions of people worldwide. The study, published in the International Journal of Molecular Sciences, sheds light on the phenomenon of anti-drug antibodies (ADAs) in psoriasis patients. According to the research, biological drugs, which
Biopharmaceuticals
GlaxoSmithKline and biotechnology company Syndivia have announced an agreement granting GSK exclusive worldwide rights to develop and commercialise a preclinical antibody-drug conjugate (ADC) for metastatic castration-resistant prostate cancer (mCRPC). The ADC, utilising Syndivia's next-generation GeminiMab conjugation technology, has shown enhanced anti-tumour activity and an encouraging safety profile, demonstrating
Biopharmaceuticals
A recent cluster randomized trial conducted during the 2008-2009 season in Canada has provided insight into the mechanism behind influenza vaccination. The study, led by researchers at McMaster University, measured the proportion of protection against influenza mediated through antibodies and other immune mechanisms. The findings suggest that influenza vaccination may
